- Home
- FMAO vs PRTA Comparison
FMAO vs PRTA Comparison
Compare FMAO & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMAO
- PRTA
- Stock Information
- Founded
- FMAO 1897
- PRTA 2012
- Country
- FMAO United States
- PRTA Ireland
- Employees
- FMAO N/A
- PRTA N/A
- Industry
- FMAO Savings Institutions
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- FMAO Finance
- PRTA Health Care
- Exchange
- FMAO Nasdaq
- PRTA Nasdaq
- Market Cap
- FMAO 369.3M
- PRTA 346.4M
- IPO Year
- FMAO N/A
- PRTA N/A
- Fundamental
- Price
- FMAO $25.85
- PRTA $6.41
- Analyst Decision
- FMAO Hold
- PRTA Buy
- Analyst Count
- FMAO 1
- PRTA 9
- Target Price
- FMAO $26.00
- PRTA $27.67
- AVG Volume (30 Days)
- FMAO 24.2K
- PRTA 1.7M
- Earning Date
- FMAO 07-31-2025
- PRTA 08-07-2025
- Dividend Yield
- FMAO 3.34%
- PRTA N/A
- EPS Growth
- FMAO 26.69
- PRTA N/A
- EPS
- FMAO 2.01
- PRTA N/A
- Revenue
- FMAO $104,144,000.00
- PRTA $137,935,000.00
- Revenue This Year
- FMAO N/A
- PRTA N/A
- Revenue Next Year
- FMAO $6.16
- PRTA $122.02
- P/E Ratio
- FMAO $13.17
- PRTA N/A
- Revenue Growth
- FMAO 9.24
- PRTA 54.55
- 52 Week Low
- FMAO $20.88
- PRTA $4.32
- 52 Week High
- FMAO $34.15
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- FMAO 55.43
- PRTA 57.61
- Support Level
- FMAO $26.18
- PRTA $5.96
- Resistance Level
- FMAO $28.24
- PRTA $6.77
- Average True Range (ATR)
- FMAO 1.05
- PRTA 0.36
- MACD
- FMAO 0.13
- PRTA 0.14
- Stochastic Oscillator
- FMAO 53.91
- PRTA 75.80
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company based in Ohio. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.